Syra Health Targets 2026 Profitability After Posting $491,221 in First Half
Key Facts
The figures in Syra Health's third-quarter results published on Nov. 3, 2026, could not be verified against a reliable disclosure that was accessible, so the record revenue, profit margin and earnings per share cited in the release headline cannot be confirmed. The company had announced on Oct. 27 that it would publish results for the three months ended Sept. 30 before the market opened on Tuesday, Nov. 3. In the latest documented quarterly results available here, Syra Health said second-quarter revenue was $2.4 million, up 23% from $1.9 million in the year-earlier period. It also reported net income of $250,242, compared with a net loss of $63,596 in the second quarter of the prior year. Those results provide context for the company's path to profitability but do not confirm third-quarter figures.
The company said second-quarter gross margin rose to 44.5% from 38.7% in the year-earlier period, an expansion of about 584 basis points year over year. It attributed the increase to revenue growth outpacing cost growth, according to its statement. The margin improvement puts second-quarter results in context for tracking operating performance, but does not establish the third-quarter level. For the first half, net income was $491,221 in the six months ended June 30, 2026, compared with a net loss of $535,861 in the same period of 2025. The shift shows the company had returned to profitability in the first half before the subsequent period's results were released.
After its first-half results, Syra Health said it still targeted profitability for fiscal 2026. It added that the timing of revenue recognition and contract milestones could continue to cause results to vary from quarter to quarter. That caution makes revenue timing an important factor in assessing quarterly results, since figures for a single quarter may not reflect the full-year trajectory. SYRA's close at $0.9298 on Nov. 2 was the latest closing price in EL7 data before the results announcement. The data do not include the stock's movement after the announcement or its trading range during the Nov. 2 session.
In September, the company announced it had won a public health analytics contract with the Mississippi State Department of Health. The contract initially runs from Sept. 2, 2026, to Sept. 1, 2029, with a maximum value of $240,000 and an option to renew for two additional one-year terms. In a separate announcement, the chief executive said Syra Health's and partner HealthSync's selection for the CMS ACCESS model could become a "sustainable ten-year revenue engine." But the agreement tied to the model was still subject to negotiations and execution of a definitive agreement when that statement was made. These developments provide background on the contracts and revenue prospects the company discussed, while the awaited third-quarter results covered the period ended Sept. 30.